Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf
Introduction<p>Chronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852025079649533952 |
|---|---|
| author | Na He (295300) |
| author2 | Guosheng Li (1419298) Jinting Liu (398001) Wancheng Liu (7213538) Ruifeng Tian (5987279) Daoxin Ma (212170) |
| author2_role | author author author author author |
| author_facet | Na He (295300) Guosheng Li (1419298) Jinting Liu (398001) Wancheng Liu (7213538) Ruifeng Tian (5987279) Daoxin Ma (212170) |
| author_role | author |
| dc.creator.none.fl_str_mv | Na He (295300) Guosheng Li (1419298) Jinting Liu (398001) Wancheng Liu (7213538) Ruifeng Tian (5987279) Daoxin Ma (212170) |
| dc.date.none.fl_str_mv | 2024-11-20T06:28:12Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2024.1452035.s002 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Image_2_COVID-19_mitigates_the_response_to_TKIs_in_patients_with_CML_via_the_inhibition_of_T-cell_immunity_pdf/27860823 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology Chronic myeloid leukemia COVID-19 BCR-ABL P210 T cell immunity TKIs |
| dc.title.none.fl_str_mv | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | Introduction<p>Chronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID-19) has challenged many cancers. However, its effect on TKI therapy of CML remains unknown.</p>Methods<p>In this study, we collected peripheral blood from chronic phase CML patients treated with TKIs at low-level BCR-ABL P210 during COVID-19 pandemic, and determined the alterations of BCR-ABL P210 by applying the well-established BCR-ABL P210 detection system.</p>Results<p>Our results showed that the level of BCR-ABL P210 of CML patients was significantly elevated shortly after contracting COVID-19, and then recovered to pre-infection level within one month. The elevated degree of P210 was positively correlated with the duration of COVID-19. And the level of P210 was elevated in CML patients that took COVID-19 vaccination. Furthermore, lymphocyte subsets and cytokine detections were performed by flow cytometry to analyze the alteration of immune responses. Our results showed that effector CD8+ T (Teff) cells were significantly downregulated while naïve CD8+ T cells or Treg cells were obviously upregulated in P210-elevated CML patients after contracting COVID-19 compared to that in P210-unchanged or decreased CML patients. Moreover, the SARS-CoV-2 pseudovirus was constructed to further determine its effects. The results showed that the level of BCR-ABL P210 was upregulated upon transfection of SARS-CoV-2 pseudovirus into blood samples of CML patients.</p>Discussion<p>Our results demonstrate that COVID-19 suppresses the immune activity and consequentially elevates the level of BCR-ABL P210 of CML patients.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_66fd2ce60c8eb0d6cd13bd014d8ac14e |
| identifier_str_mv | 10.3389/fimmu.2024.1452035.s002 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/27860823 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdfNa He (295300)Guosheng Li (1419298)Jinting Liu (398001)Wancheng Liu (7213538)Ruifeng Tian (5987279)Daoxin Ma (212170)Genetic ImmunologyChronic myeloid leukemiaCOVID-19BCR-ABL P210T cell immunityTKIsIntroduction<p>Chronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID-19) has challenged many cancers. However, its effect on TKI therapy of CML remains unknown.</p>Methods<p>In this study, we collected peripheral blood from chronic phase CML patients treated with TKIs at low-level BCR-ABL P210 during COVID-19 pandemic, and determined the alterations of BCR-ABL P210 by applying the well-established BCR-ABL P210 detection system.</p>Results<p>Our results showed that the level of BCR-ABL P210 of CML patients was significantly elevated shortly after contracting COVID-19, and then recovered to pre-infection level within one month. The elevated degree of P210 was positively correlated with the duration of COVID-19. And the level of P210 was elevated in CML patients that took COVID-19 vaccination. Furthermore, lymphocyte subsets and cytokine detections were performed by flow cytometry to analyze the alteration of immune responses. Our results showed that effector CD8+ T (Teff) cells were significantly downregulated while naïve CD8+ T cells or Treg cells were obviously upregulated in P210-elevated CML patients after contracting COVID-19 compared to that in P210-unchanged or decreased CML patients. Moreover, the SARS-CoV-2 pseudovirus was constructed to further determine its effects. The results showed that the level of BCR-ABL P210 was upregulated upon transfection of SARS-CoV-2 pseudovirus into blood samples of CML patients.</p>Discussion<p>Our results demonstrate that COVID-19 suppresses the immune activity and consequentially elevates the level of BCR-ABL P210 of CML patients.</p>2024-11-20T06:28:12ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.3389/fimmu.2024.1452035.s002https://figshare.com/articles/figure/Image_2_COVID-19_mitigates_the_response_to_TKIs_in_patients_with_CML_via_the_inhibition_of_T-cell_immunity_pdf/27860823CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/278608232024-11-20T06:28:12Z |
| spellingShingle | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf Na He (295300) Genetic Immunology Chronic myeloid leukemia COVID-19 BCR-ABL P210 T cell immunity TKIs |
| status_str | publishedVersion |
| title | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| title_full | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| title_fullStr | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| title_full_unstemmed | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| title_short | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| title_sort | Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf |
| topic | Genetic Immunology Chronic myeloid leukemia COVID-19 BCR-ABL P210 T cell immunity TKIs |